Clinician's Roundtable

Preserving kidney function in our patients with IgA nephropathy (IgAN) is absolutely critical as it reduces the burden of disease our patients face, but there’s still room for improvement when it comes to proactively preventing kidney damage. So how can we optimize our approach to reduce that burden and preserve kidney function? Joining Dr. Charles Turck to share essential strategies is Dr. Gates Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.

Food allergies and malabsorptive conditions limit food options for patients and can lead to malnutrition if alternative sources of nutrition aren’t found. So how might peptide-based formulations fit into our management approach for these GI-compromised patients? Joining Dr. Charles Turck to break down how peptide-based formulations work to improve GI tolerance, who might benefit from them, and the latest data from clinical trials is Dr. Osman Mohamed Elfadil, Senior Research Fellow in the Division of Endocrinology, Diabetes, Metabolism, and Nutrition at the Mayo Clinic in Rochester, Minnesota.

Cow’s milk protein allergy is one of the most common food allergies in childhood and can have a heavy burden on our young patients and their families. That’s why Dr. Charles Turck speaks with Dr. Anna Nowak-Wegrzyn, Director of the Pediatric Allergy Program at Hassenfeld Children’s Hospital NYU Langone, about how we can better manage these patients and address their unmet needs.

Although immunosuppressive therapy has been the backbone of IgA nephropathy (IgAN) treatment, this type of approach comes with several challenges. Here to share how non-immunosuppressive treatments could help revolutionize the IgAN treatment landscape is Dr. Gates B. Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.

The All of Us Research Program discovered associations between socioeconomic factors and visit adherence among patients with glaucoma. Can clinicians use this data to improve visit adherence? Mario Nacinovich joins Dr. Sally Baxter, an Assistant Professor of Ophthalmology and Biomedical Informatics at the University of California-San Diego, to take a look at this data.

The alternative complement pathway and the lectin pathway are the two pathways that are important in IgA nephropathy (IgAN). So how does the dysregulation of these two pathways impact disease progression, and how might this knowledge help us optimize our approach to treating patients with IgAN? Joining Dr. Charles Turck to answer those and other key questions is nephrology specialist Dr. Carl Walther.

Have you ever heard or thought that IgA nephropathy (IgAN) is only a short-term disease? Or that it’s benign? These are just some of the many common misconceptions surrounding IgAN, which is why Dr. Frank Cortazar from the New York Nephrology Vasculitis and Glomerular Center is here to help debunk these and other prevalent myths.

There are several challenges associated with the management of glomerular diseases like IgA nephropathy and C3 glomerulopathy. But in order to overcome those challenges, we must first have a firm understanding of them. That’s why Dr. Frank Cortazar from the New York Nephrology Vasculitis and Glomerular Center is here to break down those common challenges so we can work to better manage IgA nephropathy and C3 glomerulopathy.

When managing a rare disease like IgA nephropathy (IgAN), it’s essential to keep each individual patient at the center of it all, and this type of approach starts at the diagnostic stage. Joining Dr. Charles Turck to share strategies for providing patient-centered care throughout every step of the journey is Dr. Gates Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.

The All of Us Research Program discovered how socioeconomic factors such as lower income and education levels were associated with lower odds of seeing an eye doctor. Mario Nacinovich joins Dr. Sally Baxter, an Assistant Professor of Ophthalmology and Biomedical Informatics at the University of California-San Diego, to explore how socioeconomic factors could impact care for patients with glaucoma.